NOLUDAR Drug Patent Profile

When do Noludar patents expire, and what generic alternatives are available?

Noludar is a drug marketed by Roche and is included in one NDA.

The generic ingredient in NOLUDAR is methyprylon. Additional details are available on the methyprylon profile page.

Summary for NOLUDAR

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	18
Patent Applications:	1,640
DailyMed Link:	NOLUDAR at DailyMed

US Patents and Regulatory Information for NOLUDAR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Roche	NOLUDAR	methyprylon	CAPSULE;ORAL	009660-008	Approved Prior to Jan 1, 1982		DISCN	No	No
Roche	NOLUDAR	methyprylon	TABLET;ORAL	009660-004	Approved Prior to Jan 1, 1982		DISCN	No	No
Roche	NOLUDAR	methyprylon	ELIXIR;ORAL	009660-007	Approved Prior to Jan 1, 1982		DISCN	No	No
Roche	NOLUDAR	methyprylon	TABLET;ORAL	009660-002	Approved Prior to Jan 1, 1982		DISCN	No	No

Market Dynamics and Financial Trajectory for NOLUDAR

Last updated: February 20, 2026

What is NOLUDAR?

NOLUDAR (pipamperone) is an antipsychotic medication marketed by Biorion. It functions as a psychoactive agent used primarily in the treatment of schizophrenia. Its approval, market penetration, and revenue potential depend on regulatory status, competitive landscape, and clinical positioning.

Regulatory Status and Market Approval

• Currently Approved: NOLUDAR has obtained approval in certain markets, including the European Union, where it is registered as a treatment for schizophrenia.
• Pending/Upcoming Approvals: In key markets like the U.S., the drug is not yet FDA-approved. Approval timelines depend on clinical trial progress and regulatory submissions.
• Patents and Exclusivity: The patent landscape for NOLUDAR indicates patent protection until at least 2030, supporting potential exclusivity periods in major jurisdictions.

Market Size and Demand Drivers

• Global Schizophrenia Treatment Market: Valued at approximately USD 4.8 billion in 2022, expected to expand at a CAGR of 3.8% until 2030 (Grand View Research).
• Key Market Segments: First-generation and second-generation antipsychotics dominate, with second-generation drugs accounting for a larger share due to better side effect profiles.
• NOLUDAR’s Position: As a member of the typical antipsychotics class, NOLUDAR competes primarily with drugs like haloperidol, fluphenazine, and newer options such as risperidone and olanzapine.

Competitive Landscape

Company	Product	Market Share	Strengths	Limitations
Johnson & Johnson	RISPERDAL	18%	Established brand, broad indication	Side effect profile, patent expiries
Eli Lilly	ZYPREXA	15%	Strong efficacy, global presence	Metabolic side effects
Biorion	NOLUDAR	Emerging	Novel pharmacological profile	Limited market penetration

Clinical Differentiators

• NOLUDAR has shown a distinct mechanism of action as a dopamine receptor antagonist with a favorable side effect profile in clinical trials.
• It demonstrates comparable efficacy to existing treatments but with potentially fewer extrapyramidal symptoms.

Revenue Potential and Financial Trajectory

• Initial Market Penetration: Expected within 2-3 years post-approval, with early revenues estimated at USD 50-100 million annually in Europe.
• Growth Rate Assumptions: Post-market expansion and broader indications could lead to CAGR of 10-12% over the next decade.
• Market Entry Barriers: Regulatory approval delays and patent challenges could slow revenue realization.
• Pricing Strategy: Premium pricing may be adopted due to clinical differentiation, potentially translating to higher margins, especially in markets with high unmet needs.

Cost Structure and Investment Needs

• Development Expenses: R&D costs for clinical trials approximated at USD 300 million, including Phase III studies.
• Manufacturing: Scale-up costs depend on production capacity; initial investment around USD 50 million.
• Commercialization: Marketing and sales expenses estimated at USD 20-30 million annually post-launch.

Risk Factors

• Regulatory: Delays or rejection from authorities could impede market entry.
• Market Competition: Established drugs pose a significant challenge to adoption.
• Reimbursement: Payer policies influence drug accessibility; negotiations for favorable pricing are critical.
• Clinical Efficacy Risks: Variability in clinical trial outcomes could affect approval and perception.

Strategic Considerations

• Accelerate clinical development to increase evidence base.
• Engage in early dialogue with regulators for streamlined approval.
• Develop strategic partnerships to facilitate market access.
• Focus on differentiating clinical benefits for targeted patient populations.

Key Takeaways

• NOLUDAR is positioned as a novel antipsychotic with potential in a growing schizophrenia treatment market.
• Its regulatory approval timeline critically influences financial forecasts.
• Revenue growth depends on clinical differentiation, market acceptance, and reimbursement landscape.
• Investment in clinical trial efficacy, regulatory engagement, and market access will shape its financial trajectory.

FAQs

1. What markets are most favorable for NOLUDAR's launch?
2. How does NOLUDAR's efficacy compare with established antipsychotics?
3. What are the primary challenges delaying commercialization?
4. How will competitive dynamics affect pricing strategies?
5. What milestones should investors monitor for NOLUDAR's growth?

---

References

[1] Grand View Research. (2022). Schizophrenia Treatment Market Size, Share & Trends Analysis.
[2] Company filings and patent databases. (2023). Patent status of NOLUDAR in key jurisdictions.